Literature DB >> 25343550

Clinical significance of mTOR and eIF4E expression in invasive ductal carcinoma.

Aixia Hu, Miaomiao Sun, Dong Yan, Kuisheng Chen.   

Abstract

AIMS AND
BACKGROUND: Mammalian target of rapamycin (mTOR) is one of the serine-threonine protein kinases and plays an important regulatory role in cell growth. Eukaryotic translation initiation factor 4E (eIF4E) and 4E binding protein (4EBP) are the downstream proteins of mTOR signaling pathway and are the most efficient speed regulator of eukaryotic mRNA translation. The aim of the study was to investigate the clinical significance of mTOR, eIF4E and 4EBPs expression in invasive ductal carcinoma.
METHODS: Fresh biopsy specimens of invasive ductal carcinoma tissues and normal breast tissues were collected from 45 patients with breast cancer. The expressions of mTOR, eIF4E and 4EBPs in specimens were detected by an immunohistochemical SP method, and the relationship of mTOR, eIF4E and 4EBPS expressions and of their expressions with tumor metastasis were analyzed.
RESULTS: Expressions of mTOR, eIF4E and 4EBPs in invasive ductal carcinoma were significantly higher than in normal breast tissue (P <0.05). mTOR expression was positively correlated with eIF4E and 4EBP expression in invasive ductal carcinoma (P <0.05). The positive rates of mTOR, eIF4E and 4EBPs in patients with lymph node metastasis were significantly higher than in patients without lymph node metastasis (P <0.05).
CONCLUSIONS: Increased expressions of mTOR and eIF4E in invasive ductal carcinoma may be correlated with the occurrence and metastasis of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25343550     DOI: 10.1700/1660.18176

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  6 in total

1.  Prognostic significance of eukaryotic initiation factor 4E in hepatocellular carcinoma.

Authors:  Xue-Mei Jiang; Xiang-Nan Yu; Ren-Zheng Huang; Hai-Rong Zhu; Xiao-Peng Chen; Ju Xiong; Zheng-Yi Chen; Xiao-Xi Huang; Xi-Zhong Shen; Ji-Min Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-06       Impact factor: 4.553

2.  miR-34c-3p functions as a tumour suppressor by inhibiting eIF4E expression in non-small cell lung cancer.

Authors:  Fang Liu; Xuefeng Wang; Jiebing Li; Kuo Gu; Liyan Lv; Shuai Zhang; Dehai Che; Jingyan Cao; Shi Jin; Yan Yu
Journal:  Cell Prolif       Date:  2015-08-06       Impact factor: 6.831

3.  Celastrus orbiculatus extracts induce cell cycle arrest and apoptosis in human esophageal squamous carcinoma ECA-109 cells in vitro via the PI3K/AKT/mTOR signaling pathway.

Authors:  Feng Jin; Guang Zhu; Dan Li; Tengyang Ni; Xiaojun Dai; Haibo Wang; Jun Feng; Yayun Qian; Lin Yang; Shiyu Guo; Tadashi Hisamitsu; Yanqing Liu
Journal:  Oncol Lett       Date:  2017-11-21       Impact factor: 2.967

4.  The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.

Authors:  Richard E Kast; Nicolas Skuli; Samuel Cos; Georg Karpel-Massler; Yusuke Shiozawa; Ran Goshen; Marc-Eric Halatsch
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-07-11

5.  Bioinformatics analysis of dysregulated microRNAs in the nipple discharge of patients with breast cancer.

Authors:  Kai Zhang; Ya-Wen Wang; Rong Ma
Journal:  Oncol Lett       Date:  2017-03-03       Impact factor: 2.967

Review 6.  Beyond molecular tumor heterogeneity: protein synthesis takes control.

Authors:  Santiago Ramon Y Cajal; Josep Castellvi; Stefan Hümmer; Vicente Peg; Jerry Pelletier; Nahum Sonenberg
Journal:  Oncogene       Date:  2018-02-21       Impact factor: 9.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.